Pharmacological inhibition of the NLRP3 inflammasome using various inhibitors has shown reductions in RA pathology and secretion of IL-1β and TNF- α, supporting the implication of NLRP3 in RA [26, 27]. The gene discussed is NLRP3; the disease is rheumatoid arthritis.